Lack of Written-Description Support for Claimed Ranges Makes Parent Application Prior Art
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
INDIVIOR UK LIMITED v. DR. REDDY'S LABORATORIES S.A.
Before Lourie, Linn, and Dyk. Appeal from the Patent Trial and Appeal Board.
Summary: Claims of a continuation application were anticipated because they were not entitled to the filing date of a parent application that failed to support the ranges of numerical values claimed in the continuation.
Dr. Reddy’s Laboratories petitioned for inter partes review (IPR) of Indivior’s patent claims. The Board held that the challenged claims, which issued from a continuation application, were not entitled to the filing date of a parent application. According to the Board, the parent application lacked written-description support for numerical ranges recited in the challenged claims, so the parent application was prior art. Because the parent application disclosed values within the claimed ranges, the Board held that it anticipated the challenged claims. Indivior appealed.
The Federal Circuit found substantial evidence for the Board’s factual findings concerning the lack of written-description support. Although some of the claimed ranges could be derived mathematically from certain entries in a table from the parent application, the Federal Circuit held that this table was insufficient to support the claimed ranges.
Judge Linn dissented, arguing that the majority ignored two precedential cases showing that the parent application provided adequate support for the claimed ranges.
Editor: Paul Stewart
Written by: Benjamin L. Black & Jeremy Anapol
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…